Bullous pemphigoid after SARS‐CoV‐2 vaccination: spike‐protein‐directed immunofluorescence confocal microscopy and T‐cell‐receptor studies
Thilo Gambichler, Nazha Hamdani, Heidi Budde, Marcel Sieme, Marina Skrygan, L. Scholl, Heinrich Dickel, Bertold Behle, Nomun Ganjuur, Christina Scheel, Nessr Abu Rached, Lennart Ocker, René Stranzenbach, Martin Doerler, L. Pfeiffer, Jürgen C. Becker
Abstract
improve beyond week 24. Limitations of the study include a slower-than-expected enrolmentpossibly because ADA monotherapy was the preferred approach of Canadian dermatologists to treat psoriasisand the single-arm study design as each participant served as their own control, and outcomes after addition of MTX are compared with similar assessments at baseline. The variability in MTX dosing based on investigator judgement may have been another limitation.
Topics & Concepts
MedicineLibrary scienceDermatologic surgeryDermatologyComputer scienceAutoimmune Bullous Skin DiseasesAntifungal resistance and susceptibilityT-cell and B-cell Immunology